November 8, 2022
Consolidated Financial Results for the Second Quarter of Fiscal 2022
(Six-Month Period Ended September 30, 2022) [JGAAP]
Company name: | KAKEN PHARMACEUTICAL CO., LTD. |
Stock exchange listing: | Tokyo Stock Exchange |
Securities code number: | 4521 |
URL: | https://www.kaken.co.jp/ |
Representative: | Hiroyuki Horiuchi, President and Representative Director |
Contact: | Kazuhiro Kondo, General Manager of General Affairs Department |
Telephone: | +81-3-5977-5002 |
Scheduled date of quarterly securities report submission: | November 11, 2022 |
Scheduled date of dividend payment commencement: | November 30, 2022 |
Supplementary materials for quarterly financial results: | Yes |
Quarterly financial results briefing: | Yes (for institutional investors and analysts) |
(Amounts are rounded down to the nearest million yen)
1. Consolidated Financial Results for the Six-Month Period of Fiscal 2022 (April 1, 2022 to September 30, 2022)
(1) Consolidated Operating Results (cumulative) | (Percentage indicates year-on-year change) | |||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | |||||||
owners of the Company | ||||||||||
(Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | |||
Six-Month period of Fiscal 2022 | 36,819 | (2.0) | 8,209 | (9.2) | 8,555 | (7.9) | 5,964 | (11.3) | ||
Six-Month period of Fiscal 2021 | 37,588 | 2.2 | 9,036 | (7.6) | 9,290 | (7.2) | 6,721 | (7.0) | ||
Note: | ||||||||||
Comprehensive income: | ||||||||||
Six-Month period of Fiscal 2022: | ¥ 6,209 million [(15.0)%] | |||||||||
Six-Month period of Fiscal 2021: | ¥ 7,306 million [(10.2)%] | |||||||||
Basic earnings | Diluted earnings | |||||||||
per share | per share | |||||||||
(Yen) | (Yen) | |||||||||
Six-Month period of Fiscal 2022 | 158.34 | - | ||||||||
Six-Month period of Fiscal 2021 | 176.24 | - | ||||||||
(2) Consolidated Financial Position | ||||||||||
Total assets | Net assets | Equity-to-asset ratio | ||||||||
(Million yen) | (Million yen) | (%) | ||||||||
As of September 30, 2022 | 167,307 | 140,384 | 83.6 | |||||||
As of March 31, 2022 | 165,181 | 138,325 | 83.4 |
Reference:
Equity:
As of September 30, 2022: ¥ 139,806 million
As of March 31, 2022: ¥ 137,747 million
1
2. Cash Dividends
Annual dividends per share | ||||||
1st quarter | 2nd quarter | 3rd quarter | Year-end | Total | ||
(Yen) | (Yen) | (Yen) | (Yen) | (Yen) | ||
Year ended March 31, | - | 75.00 | - | 75.00 | 150.00 | |
2022 | ||||||
Year ending March 31, | - | 75.00 | ||||
2023 | ||||||
Year ending March 31, | - | 75.00 | 150.00 | |||
2023 (Forecast) | ||||||
Note: Revisions to the forecast of cash dividends most recently announced: None
3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2023 (April 1, 2022 to March 31, 2023)
(Percentage indicates year-on-year change)
Profit attributable to | Basic | |||||||||
Net sales | Operating profit | Ordinary profit | earnings | |||||||
owners of the Company | ||||||||||
per share | ||||||||||
(Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | (Yen) | ||
Year ending | 76,400 | 0.5 | 15,000 | (12.1) | 15,500 | (11.6) | 12,000 | 25.7 | 320.23 | |
March 31, 2023 | ||||||||||
Note: Revisions to the financial forecast most recently announced: None
2
* Notes
- Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the changes in scope of consolidation): None
- Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes
- Changes in accounting policies, changes in accounting estimates, and restatement
- Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
- Changes in accounting policies other than 1): None
- Changes in accounting estimates: None
- Restatement: None
- Number of issued shares (common stock)
- Number of issued shares at the end of the period (including treasury stock)
- Number of treasury shares at the end of the period
- Average number of shares during the period
As of September 30, | 45,939,730 shares | As of March 31, | 45,939,730 shares |
2022 | 2022 | ||
As of September 30, | 8,466,470 shares | As of March 31, | 8,121,361 shares |
2022 | 2022 | ||
Six-Month period of | 37,668,779 shares | Six-Month period of | 38,138,439 shares |
Fiscal 2022 | Fiscal 2021 | ||
Note: The number of treasury shares at the end of the period includes the Company's shares held by the "Board Benefit Trust (BBT)" (33,400 shares as of September 30, 2022 and 38,500 shares as of March 31, 2022). The Company's shares held by the BBT are included in the number of treasury stock to be deducted in the calculation of the average number of shares during the period (36,633 shares as of September 30, 2022 and 39,051 shares as of September 30, 2021).
- Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants or an audit corporation.
- Explanation of proper use of earnings forecasts, and other special matters:
(Caution regarding forward-looking statements)
The performance forecasts and other descriptions on future events presented in this material are based on information currently available and certain assumptions considered to be reasonable. The actual performance may differ from these forecasts.
How to review the supplementary material to the quarterly financial results reports:
It has been posted on the Company's web site, along with the quarterly financial results reports.
3
2. Consolidated Financial Results for Six-Month Period of Fiscal 2022
(1) Consolidated balance sheets
(Millions of yen)
Fiscal 2021 | Six-Month Period of | |||
Fiscal 2022 | ||||
(As of March 31, 2022) | ||||
(As of September 30, 2022) | ||||
Assets | ||||
Current assets | ||||
Cash and deposits | 61,025 | 60,768 | ||
Notes and accounts receivable - trade, and | 20,260 | 20,541 | ||
contract assets | ||||
Marketable securities | 13,599 | 14,699 | ||
Merchandise and finished goods | 5,807 | 6,850 | ||
Work in process | 2,964 | 2,619 | ||
Raw materials and supplies | 6,209 | 6,686 | ||
Other | 746 | 859 | ||
Allowance for doubtful accounts | - | (0) | ||
Total current assets | 110,613 | 113,024 | ||
Non-current assets | ||||
Property, plant and equipment | ||||
Buildings and structures, net | 17,142 | 16,718 | ||
Other, net | 8,591 | 8,466 | ||
Total property, plant and equipment | 25,734 | 25,185 | ||
Intangible assets | ||||
In-process research and development | 7,300 | 7,300 | ||
Other | 936 | 991 | ||
Total intangible assets | 8,236 | 8,291 | ||
Investments and other assets | ||||
Investment securities | 17,093 | 17,398 | ||
Other | 3,503 | 3,407 | ||
Total investments and other assets | 20,596 | 20,805 | ||
Total non-current assets | 54,567 | 54,282 | ||
Total assets | 165,181 | 167,307 |
4
(Millions of yen)
Fiscal 2021 | Six-Month Period of | ||||||||||
Fiscal 2022 | |||||||||||
(As of March 31, 2022) | |||||||||||
(As of September 30, 2022) | |||||||||||
Liabilities | |||||||||||
Current liabilities | |||||||||||
Notes and accounts payable-trade | 5,861 | 6,656 | |||||||||
Electronically recorded obligations-operating | 78 | 105 | |||||||||
Short-term bank loans | 3,850 | 3,850 | |||||||||
Income taxes payable | 2,436 | 2,631 | |||||||||
Provision for bonuses | 984 | 922 | |||||||||
Other | 5,838 | 5,068 | |||||||||
Total current liabilities | 19,049 | 19,234 | |||||||||
Non-current liabilities | |||||||||||
Provision for share-based remuneration | 106 | 70 | |||||||||
Net defined benefit liability | 5,039 | 4,945 | |||||||||
Deferred tax liabilities | 2,229 | 2,229 | |||||||||
Other | 431 | 443 | |||||||||
Total non-current liabilities | 7,806 | 7,688 | |||||||||
Total liabilities | 26,855 | 26,922 | |||||||||
Net assets | |||||||||||
Shareholders' equity | |||||||||||
Common stock | 23,853 | 23,853 | |||||||||
Capital surplus | 11,406 | 11,406 | |||||||||
Retained earnings | 126,347 | 129,472 | |||||||||
Treasury stock | (28,714) | (30,025) | |||||||||
Total shareholders' equity | 132,893 | 134,707 | |||||||||
Accumulated other comprehensive income | |||||||||||
Net unrealized holding gain on securities | 4,551 | 4,765 | |||||||||
Remeasurements of defined benefit plans | 301 | 333 | |||||||||
Total accumulated other comprehensive | 4,853 | 5,099 | |||||||||
income | |||||||||||
Non-controlling interests | 578 | 578 | |||||||||
Total net assets | 138,325 | 140,384 | |||||||||
Total liabilities and net assets | 165,181 | 167,307 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Kaken Pharmaceutical Co. Ltd. published this content on 08 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2022 02:30:05 UTC.